Clinical Trial Update: HDR Brachytherapy Plus Stereotactic Ablative Prostate Radiotherapy for Patients With Intermediate and High-risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating HDR brachytherapy plus stereotactic ablative radiotherapy for intermediate and high-risk prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Prostatic Neoplasm

Snippet

Sponsor: David Büchser | Conditions: Prostatic Neoplasm | Phase 2 | Status: UNKNOWN